Journey Medical expands Emrosi payer coverage to 65% of commercial lives from 29% in May 2025

Journey Medical Corp

Emrosi now has pharmacy benefit coverage for 65% of 187 million U.S. commercial lives, up from 29% in May 2025.
Expanded coverage expected to drive further growth in total prescription demand for rosacea treatment.
CEO cites targeted contracting strategy, increasing prescription demand, and superior clinical data as drivers.
Emrosi is available by prescription at specialty pharmacy chains.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.